Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join


Mar 29, 2023 10:00 AM - Mar 31, 2023 4:15 PM

(US Eastern Standard Time)

DIA/FDA Biostatistics Industry and Regulator Forum

Join us virtually from the comfort of your home/office March 29-31 or watch later at a time that works for you. This event provides access to the materials for a full two months!

Session 2: Complex Innovative Trials Designs: Current Perspectives and Future Directions

Session Chair(s)

Anup  Amatya, PhD

Anup Amatya, PhD

Lead Mathematical Statistician

FDA, United States

Lisa  Hampson, PhD

Lisa Hampson, PhD

Senior Director, Advanced Methodology & Data Science

Novartis Pharma AG, Switzerland

Any trial design that improves the speed, efficiency, or flexibility of drug development over the standard randomized controlled trial design could be described as innovative. Novel approaches to clinical trial designs may be needed to bring new treatments to patients faster, particularly in often rare and more targeted patient populations. Complex innovative trials may feature the use of early surrogate endpoints, adaptive designs permitting mid-study changes to the trial based on accruing data, Bayesian methods leveraging trial-external information, and master protocols studying several treatments or disease subtypes under the same overarching protocol. The use of the ICH E9(R1) estimand framework remains relevant for complex innovative designs when the objective is to estimate a treatment effect, where trials answering several questions will have multiple estimands which may evolve during the trial as a result of pre-planned adaptations. In this session, through discussion and case-studies, we will explore innovative approaches to clinical trial design and review how the estimand framework can be applied to complex innovative trials.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Discuss regulatory perspectives on innovations in clinical trials
  • Identify issues relevant to applying the ICH E9(R1) framework to complex innovative trials
  • Explain Bayesian approaches to complex clinical trial design
  • Discuss practical issues associated with the implementation of complex innovative designs


Dionne  Price, PhD


Dionne Price, PhD

FDA, United States

Deputy Director, Office of Biostatistics, OTS, CDER

Olivier  Collignon


Olivier Collignon

GlaxoSmithKline, United Kingdom


Melanie  Quintana, PhD

Complex Innovative Trials Designs: Current Perspectives and Future Directions

Melanie Quintana, PhD

Berry Consultants, LLC, United States

Director & Senior Statistical Scientist

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.